Project description
Novel biomarkers for stratifying neuropsychiatric disorders
Classification of neuropsychiatric disorders such as schizophrenia, where core biology remains relatively unknown, mainly depends on neuroimaging biomarkers and clinical endpoints. The use of quantitative biomarkers would not only assist in disease classification but also help drug development efforts. The EU-funded PRISM 2 project will capitalise on the knowledge generated by its predecessor PRISM 1 project on diagnostic and social functioning biomarkers for schizophrenia and Alzheimer’s disease and aim to extend it to major depressive disorders. The goal is to identify reliable biomarkers to help in the diagnosis and personalised treatment of neuropsychiatric disorders.
Objective
The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.
Fields of science
Not validated
Not validated
Keywords
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
9712CP Groningen
Netherlands
See on map
Participants (17)
OX10 8BA Wallingford
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
OX10 8BA Wallingford
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6525 GA Nijmegen
See on map
28029 Madrid
See on map
40126 Bologna
See on map
1081 HV Amsterdam
See on map
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35000 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
OX9 3WT Thame
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
82256 Furstenfeldbruck
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2333 ZA Leiden
See on map
3584 BK Utrecht
See on map
02142 CAMBRIDGE MA
See on map
55218 Ingelheim
See on map
NY10591 Tarrytown
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.